Co-delivery of amphipol-conjugated adjuvant with antigen, and adjuvant combinations, enhance immune protection elicited by a membrane protein-based vaccine against a mucosal challenge with Chlamydia. Issue 45 (29th October 2018)

• Record Type: Journal Article
• Authors: Tifrea, Delia F.; Pal, Sukumar; Le Bon, Christel; Giusti, Fabrice; Popot, Jean-Luc; Cocco, Melanie J.; Zoonens, Manuela; de la Maza, Luis M.
• Is Part Of: Vaccine. Volume 36:Issue 45(2018)
• Page Start: 6640
• Page End: 6649
• Publication Date: 2018-10-29
• Subjects: Chlamydia -- Vaccine -- Amphipols -- A8-35 -- Adjuvant -- EP-67 -- MOMP; Vaccines -- Periodicals; 615.372
• DOI: 10.1016/j.vaccine.2018.09.055
• Languages: English
• ISSNs: 0264-410X

Abstract

Abstract: Introduction: Chlamydial infections are spread worldwide and a vaccine is needed to control this pathogen. The goals of this study were to determine if the delivery of an adjuvant associated to the antigen, via a derivatized amphipol, and adjuvant combinations improve vaccine protection. Methods: A novel approach, trapping the Chlamydia muridarum ( Cm ) native MOMP (nMOMP) with amphipols (A8-35), bearing a covalently conjugated peptide (EP67), was used. Adjuvants incorporated were: EP67 either conjugated to A8-35, which was used to trap nMOMP (nMOMP/EP67-A8-35), or free as a control, added to nMOMP/A8-35 complexes (nMOMP/A8-35+EP67); Montanide ISA 720 to enhance humoral responses, and CpG-1826 to elicit robust cell-mediated immunity (CMI). BALB/c mice were immunized by mucosal and systemic routes. Intranasal immunization with live Cm was used as positive control and three negative controls were included. Mice were challenged intranasally with Cm and changes in body weight, lungs weight and number of Cm -inclusion forming units (IFU) recovered from the lungs were evaluated to establish protection. To assess local responses levels of IFN- γ and Cm -specific IgA were determined in lungs' supernatants. Results: Structural assays demonstrated that nMOMP secondary structure and thermal stability were maintained when A8-35 was covalently modified. Mice vaccinated with nMOMP/EP67-A8-35 were better protected than animals immunized with nMOMP/A8-35+EP67. Addition of Montanide enhanced Th2 responses and improved protection. Including CpG-1826 further broadened, intensified and switched to Th1-biased immune responses. With delivery of nMOMP and the three adjuvants, as determined by changes in body weight, lungs weight and number of IFU recovered from lungs, protection at 10 days post-challenge was equivalent to that induced by immunization with live Cm . Conclusions: Covalent association of EP67 to A8-35, used to keep nMOMP water-soluble, improves protection over that conferred by free EP67. Adjuvant combinations including EP67+Montanide+CpG-1826, by broadening and intensifying cellular and humoral immune responses, further enhanced protection.